Dynamic Contrast-Enhanced Fluorescence Arthroscopy of Meniscus Pilot
Knee Injuries
About this trial
This is an interventional other trial for Knee Injuries focused on measuring meniscus, Indocyanine green, fluorescence, imaging
Eligibility Criteria
Inclusion Criteria:
- Patients 18 years of age or older.
- Meniscal tear based on MRI or preoperative assessment
- Provision of informed consent.
Exclusion Criteria:
- Inability of patient to provide informed consent
- Iodine allergy.
- Evidence of septic arthritis of the proposed surgical joint.
- Burns.
- Incarceration.
- Expected survival of less than 90 days.
- Problems, in the judgment of study personnel, with maintaining follow-up with the patient.
- Pregnant or Breastfeeding Women
Sites / Locations
- Dartmouth Hitchcock Medical CenterRecruiting
Arms of the Study
Arm 1
Experimental
Patients with a meniscal tear requiring surgery
Patients will be administered Food and Drug Administration (FDA) approved Indocyanine green (ICG) through intravenous injection and imaged by a FDA approved surgical fluorescence imaging device. Both ICG fluorescence and the imaging system have been used for routine clinical practice for many years. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to meniscal perfusion can be captured by an arthroscopic imaging system.